Xact Kapitalforvaltning’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
$9.71M Sell
297,677
-11,703
-4% -$457K 0.21% 94
2019
Q4
$14M Buy
309,380
+17,490
+6% +$732K 0.24% 83
2019
Q3
$11.9M Buy
291,890
+22,162
+8% +$939K 0.23% 88
2019
Q2
$11.6M Buy
269,728
+19,106
+8% +$735K 0.24% 82
2019
Q1
$9.62M Buy
250,622
+794
+0.3% +$30.3K 0.22% 89
2018
Q4
$8.83M Buy
249,828
+1,537
+0.6% +$55.7K 0.23% 77
2018
Q3
$9.56M Sell
248,291
-865
-0.3% -$30.2K 0.2% 97
2018
Q2
$8.15M Sell
249,156
-11,288
-4% -$340K 0.17% 118
2018
Q1
$7.12M Buy
260,444
+16,667
+7% +$453K 0.16% 126
2017
Q4
$6.04M Buy
243,777
+15,308
+7% +$422K 0.14% 151
2017
Q3
$6.66M Buy
228,469
+4,128
+2% +$114K 0.19% 121
2017
Q2
$6.22M Buy
224,341
+2,770
+1% +$73.5K 0.19% 120
2017
Q1
$5.51M Buy
221,571
+11,808
+6% +$287K 0.17% 134
2016
Q4
$4.54M Buy
209,763
+4,205
+2% +$91.8K 0.16% 143
2016
Q3
$4.89M Buy
+205,558
New +$4.9M 0.17% 130

Other funds holding BSX

Xact Kapitalforvaltning's BSX Position: Q1 2020 in Review

Xact Kapitalforvaltning reduced its Boston Scientific (BSX) stake by 3.8% in Q1 2020, selling an estimated $457K and leaving 297,677 shares worth $9.71M. The position accounts for 0.21% of the portfolio, ranked #94.

Xact Kapitalforvaltning first reported a position in BSX in Q3 2016 and has held it in 15 quarters since. The position peaked at $14M in Q4 2019. 801 funds tracked by Wall St. Rank hold BSX as of Q1 2020.

  • Xact Kapitalforvaltning held 297,677 shares of Boston Scientific worth $9.71M as of Q1 2020.
  • Xact Kapitalforvaltning sold 11,703 Boston Scientific shares in Q1 2020, an estimated $457K.
  • Boston Scientific made up 0.21% of Xact Kapitalforvaltning's portfolio in Q1 2020, its #94 holding.
  • Xact Kapitalforvaltning first reported a position in Boston Scientific in Q3 2016 and has held it in 15 quarters since.
  • Xact Kapitalforvaltning's Boston Scientific position peaked at $14M in Q4 2019.
  • 801 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2020.

Based on Xact Kapitalforvaltning's 13F filing for Q1 2020, filed 14 May 2020.